Evidence map›Paper›PMID 39425074›Full record

ArticleBMC public health2024

The acceptance of COVID-19 vaccines in Rwanda: a cross-sectional study.

Edward Mbonigaba, Fengyun Yu, Mark Donald C Reñosa, Ivan Emil Mwikarago, Frederick Nchang Cho, Peter Canisius Kuku Elad, Wolfram Metzger, Richard Muhindo, Qiushi Chen, Claudia M Denkinger and 2 more

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Edward MbonigabaCentre of Infectious Diseases, Division of Infectious Disease and Tropical Medicine, Universität Heidelberg, Heidelberg, Germany. edwardnkwaya@gmail.com.
Fengyun YuInterdisciplinary Centre for Scientific Computing, Universität Heidelberg, Heidelberg, Germany.
Mark Donald C ReñosaHeidelberg Institute of Global Health, Universität Heidelberg, Heidelberg, Germany.
Ivan Emil MwikaragoCollege of Medicine and Health Sciences, School of Public Health, University of Rwanda, Kigali, Rwanda.
Frederick Nchang ChoCameroon Baptist Convention Health Services - HIV free/Strengthening Public Health Laboratory Systems, Kumba, Cameroon.
Peter Canisius Kuku EladCameroon Baptist Convention Health Services - HIV free/Strengthening Public Health Laboratory Systems, Kumba, Cameroon.
Wolfram MetzgerDepartment of Internal Medicine IV, Eberhard-Karls Universität Tübingen, Tübingen, Germany.
Richard MuhindoDepartment of Nursing Institute, College of Health Sciences, Makerere University, P.O BOX 7072, Kampala, Uganda.
Qiushi ChenThe Harold and Inge Marcus Department of Industrial and Manufacturing Engineering, The Pennsylvania State University, United States of America, University Park, Harrisburg, PA, United States of America.
Claudia M DenkingerCentre of Infectious Diseases, Division of Infectious Disease and Tropical Medicine, Universität Heidelberg, Heidelberg, Germany.
Shannon A McMahonCentre of Infectious Diseases, Division of Infectious Disease and Tropical Medicine, Universität Heidelberg, Heidelberg, Germany.
Simiao ChenCentre of Infectious Diseases, Division of Infectious Disease and Tropical Medicine, Universität Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first reported case of Coronavirus Disease 2019 (COVID-19) in Rwanda occurred on March 14 2020. By the end of July 2024, a total of 133,518 individuals had tested positive for the infection, resulting in 1,468 deaths and 132,039 had fully recovered. The success of COVID-19 elimination in Rwanda hinges on the public's level of acceptance of the COVID-19 vaccination. Although COVID-19 is no longer a pandemic anymore, the World Health Organisation recommends countries vaccinate their populations to protect them from COVID-19 and its variants. Globally, COVID-19 has affected 704,753,890 people, caused 7,010,681 deaths and 675,619,811 have recovered. This study aimed to assess the acceptability of COVID-19 vaccines among adults aged 18 years and above in Rwanda. A cross-sectional study was conducted from January to March 2022 to determine the associations between COVID-19 vaccine acceptance (VA) with respondents' characteristics, using logistic regression analysis. This study enrolled 2,126 respondents with a mean age of 31 years, the majority of whom were females (82.2%), 51.4% had completed primary education, and 78.7% were married. Most respondents recognized the importance of COVID-19 vaccination for both personal health and community well-being. The study found a high rate of COVID-19 vaccine acceptance, with 91.6% of respondents expressing VA and an overall VA rate of 98.2%. Having a relationship with the child(ren) was the only characteristic associated with COVID-19 vaccine acceptance (p; 3.2 × 10

Indexed as

COVID-19COVID-19 VaccinesAdolescentAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPatient Acceptance of Health CareRwandaSARS-CoV-2Surveys and QuestionnairesVaccination HesitancyYoung AdultCOVID-19 VaccinesAcceptabilityCOVID-19RwandaVaccinationVaccine acceptance

Identifiers

PMID39425074
PMCPMC11490121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.